Merck & Co., Inc.
Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%
Merck Noxafil (posaconazole, legacy) by Year
Noxafil (posaconazole, legacy) — U.S. reported growth YoY (%) (%)
Merck Noxafil (posaconazole, legacy): -78.0% in FY2024, down 41.0 pts from a year earlier. No newer figure appears in the documents we track.
Where the FY2024 figure comes from
“|| Noxafil | 177 | 213 | -17 | 7 | 32 | -78 | 170 | 181 | -6”
Source: Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Reported in Form 8-K Table 3a / 3b Product Sales.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Noxafil (posaconazole, legacy) — U.S. reported growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2024 | Dec 31, 2024 | -78.0% | -41.0 pts | Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗ |
| FY2023 | Dec 31, 2023 | -37.0% | – | Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗ |
| FY2021 | Dec 31, 2021 | 42.0% | – | Form 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗ |
| FY2019 | Dec 31, 2019 | -20.0% | -34.0 pts | Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗ |
| FY2018 | Dec 31, 2018 | 14.0% | +5.0 pts | Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗ |
| FY2017 | Dec 31, 2017 | 9.0% | – | Form 8-K (a18-5152_1ex99d1.htm, filed 2018-02-02) ↗ |
Cite this data
StockData. (2026). Merck Noxafil (posaconazole, legacy) (%), annual FY2017–FY2024 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-noxafil-us-nom-yoy
See every metric in the Merck KPI table. Data updated Oct 26, 2026.